Graft-Versus-Host Disease
"Possible Higher Risk for African American Patients."
Published in Cancer Weekly, November 4th, 1996
According to the authors' abstract of an article published in Cancer, "Background: Race is not generally recognized as a factor in the severity or incidence of graft-versus-host disease (GVHD) after allogeneic bone marrow transplantation. The impression that African American patients had more frequent and severe GVHD prompted this retrospective survey. Methods: The records of 75 consecutive patients treated with a human leukocyte antigen-identical sibling bone marrow transplant from 1985 to 1993 were reviewed. GVHD prophylaxis uniformly employed cyclosporine and steroids. Treatment of GVHD included cyclosporine and high dose steroids in all cases. Antithymocyte...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
Source: Cancer Weekly (1996-11-04)
More Articles from Cancer Weekly
- Cancer Gene Therapy
Adenovirus-Mediated IL-12 Gene Therapy for Metastatic Colon Cancer - Cancer Gene Therapy
Gene Gun Tested in Cancer Patients - Cancer Gene Therapy
Primary Brain Tumors Susceptible to Genetically Engineered HSV - Cancer Gene Therapy
Modified Cold Virus Is Turned into Cancer Killer - Acute Myeloid Leukemia
Multidimensional Flow Cytometry Useful in AML Relapse - Anal Cancer (Combination Therapy)
Radiotherapy/Chemotherapy Recommended for Cancer Patients - More from this issue of Cancer Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
